Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compugen ( (CGEN) ) has provided an update.
Compugen Ltd. reported its second quarter 2025 financial results on August 6, 2025, highlighting significant advancements in its immuno-oncology pipeline. The company dosed the first patient in its MAIA-ovarian trial for COM701 and is preparing to present a pooled analysis of Phase 1 trials at ESMO 2025. Compugen’s partner, AstraZeneca, is progressing with its rilvegostomig program, which could become a significant revenue source for Compugen. Financially, the company maintains a solid position with a cash runway expected to fund operations into 2027, despite a decrease in revenue compared to the previous year.
The most recent analyst rating on (CGEN) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Neutral.
The overall stock score is influenced significantly by the company’s financial performance and technical analysis. While strategic partnerships and improved cash flow management are promising, ongoing profitability challenges and valuation concerns weigh on the stock’s attractiveness.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen Ltd. is a clinical-stage cancer immunotherapy company based in Holon, Israel, known for its pioneering work in predictive computational target discovery powered by AI/ML. The company focuses on developing innovative immuno-oncology therapies and has a strategic partnership with AstraZeneca.
Average Trading Volume: 243,294
Technical Sentiment Signal: Strong Sell
Current Market Cap: $138.4M
See more insights into CGEN stock on TipRanks’ Stock Analysis page.